Active Rheumatoid Arthritis
Conditions
Interventions
RGB-19 or Tocilizumab
Sponsors
Karibe Yusuke
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Male or Female patients from 20 years to 75 years of age (both inclusive) when signing Informed Consent. Active RA patients. Patients who have an inadequate response to MTX.
Exclusion criteria
Exclusion criteria: Patients who have received treatment with two or more biological DMARDs/their biosimilar products. Patients who have ever received tocilizumab, any other IL-6 inhibitors or IL-6 receptor inhibitors, or Janus kinase inhibitors in the past. Patients who are pregnant or possibly pregnant and/or breast-feeding, or patients planning to become pregnant during the study period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean Change from baseline in DAS28-ESR at Week 12 after the first administration of investigational product | — |
Contacts
Public ContactPublic Relations
Mochida Pharmaceutical Co., Ltd.
Outcome results
None listed